Services
Genetics and Biomarkers
Eleven P15 focuses on the development of biomarkers that enable early detection of idiopathic pulmonary fibrosis, and the discovery of genetically-targeted therapeutic approaches to treat and prevent this incurable disease.
Overview
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and localized to the lung. IPF is a fatal disease with median survival at 3-5 years. Two drugs have been approved for treatment of IPF, but these drugs fail to reverse scarred lung tissue or to improve survival. Accurate diagnosis of IPF is challenging. In a national IPF survey, 42% endured a year or more between first experienced symptoms and diagnosis; 55% were misdiagnosed at least once.
Eleven P15
Scientific Team
IPF Genetics: David Schwartz, MD
Mucus Biology: Chris Evans, PhD
Biomarkers: Ivana Yang, PhD
Genetics: Tasha Fingerlin, PhD
Chief Officers
CEO: Bruce Schroffel, MS/MPH
CSO: David Schwartz, MD